Skip to main content
. Author manuscript; available in PMC: 2020 Oct 8.
Published in final edited form as: J Urol. 2019 Jun;201(6):1127–1133. doi: 10.1097/JU.0000000000000110

Table 5.

Univariable and Multivariable Competing Risks Regression for PSA Failure

Univariable PSA Failure Multivariable PSA Failure
HR [95% CI] p-value HR [95% CI] p-value

Biopsy Result Positive 4.39 [3.00 – 6.42] <.001 3.87 [2.56 – 5.85] <.001
Negative REF REF
Gleason Score >=7 1.47 [1.01 – 2.14] 0.043 1.44 [0.96 – 2.17] 0.08
<=6 REF REF
Pre-RT PSA (ng/mL) 10–20 1.23 [0.81 – 1.85] 0.60 1.21 [0.79 – 1.86] 0.37
>=20 1.16 [0.71 – 1.90] 1.40 [0.78 – 2.52] 0.26
0–10 REF REF
T-Stage T3 1.08 [0.69 – 1.68] 0.75 0.81 [0.48 – 1.36] 0.43
T1-T2 REF REF
Hormones No 1.66 [1.14 – 2.42] 0.009 1.63 [1.07 – 2.49] 0.023
Yes REF REF
NCCN Risk Score High 1.97 [1.07 – 3.60] 0.07 ---
Medium 1.52 [0.82 – 2.81] ---
Low REF ---